M&T Bank Corp Erasca, Inc. Transaction History

M&T Bank Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$3.89 - $8.57 $1,443 - $3,179	-371 Reduced 0.64%	57,966 $249,000
Q4 2022 Feb 13, 2023	BUY	$3.89 - $8.57 $34,453 - $75,904	8,857 Added 17.9%	58,337 $251,000
Q3 2022 Nov 14, 2022	BUY	$5.82 - $10.68 $139,330 - $255,679	23,940 Added 93.74%	49,480 $386,000
Q2 2022 Aug 05, 2022	BUY	$4.58 - $8.72 $116,973 - $222,708	25,540 New	25,540 $142,000

117

74.3M

7.1K

40.1K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $265M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

Stay updated on M&T Bank Corp with notifications on news.